Multiply Labs, a robotics company developing industry-leading automated manufacturing systems to produce individualized drugs, and Akron Bio (“Akron”), a leading supplier of critical materials and services for advanced therapies, today announced a non-exclusive partnership focused on automating and standardizing the use of cytokines in cell therapy manufacturing.

Leveraging Multiply Labs' cell therapy robotic cluster, this partnership will enable Akron’s cytokines, starting with cGMP-compliant rHu Interleukin-2 (IL-2), to be automated with the use of robotics. Multiply Labs’ robotic systems will incorporate Akron’s liquid IL-2 into its cell therapy manufacturing workflow in an aseptic manner, precisely formulating and dispensing the right amount for any given process.

“At Akron Bio, we are inspired by the transformative impact that advanced therapies have on patients and families in need, and we are eager to enable greater access to these life-saving treatments,” said Ezequiel Zylberberg, Vice President of Corporate Development at Akron Bio. “Our partnership with Multiply Labs will allow us to integrate Akron’s cGMP materials into cell therapy manufacturing workflows - simplifying delivery and reducing risk to patients.”

Akron and Multiply Labs will partner to integrate Akron’s existing cGMP-compliant cytokines with Multiply Labs’ proprietary adapter system, thereby making these materials compatible with Multiply Labs’ cell therapy robotic clusters. Manufacturers already using Akron’s products will be able to use these automated syringes with their current equipment, without substantially changing their overall process for cell therapy manufacturing.

“We are excited to collaborate with Akron due to their industry leading GMP experience and regulatory competence in the challenging field of manufacturing biological proteins crucial for cell therapy,” said Fred Parietti, PhD, Co-Founder and CEO of Multiply Labs. “This strategic partnership signifies a fundamental step in our journey to pioneer a fully automated end-to-end process, addressing the critical role of advanced, GMP-proven reagents in cell therapy manufacturing.”